Influenza vaccines: from whole virus preparations to recombinant protein technology

References

• Stohr K. Preventing and treating influenza. BMJ 326(7401), 1223–1224 (2003).
   PubMed Web of Science ®Google Scholar
• Both GW, Sleigh MJ, Cox NJ et al. Antigenic drift in influenza virus H3 hemagglutinin from 1968–1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol. 48(1), 52–60 (1983).
   PubMed Web of Science ®Google Scholar
• Underwood PA. Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies. J. Gen. Virol. 62(Pt 1), 153–169 (1982).
   PubMed Web of Science ®Google Scholar
• McLean WM, Francis T. Influenza virus vaccine production. Problems 157–159 (1950).
   Google Scholar
• Davenport FM. Inactivated influenza virus vaccines. Past, present, and future. Am. Rev. Respir. Dis. 83(2)(Pt 2), 146–156 (1961).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis. 39(7), 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21(16), 1776–1779 (2003).
   PubMed Web of Science ®Google Scholar
• Drape RJ, Macklin MD, Barr LJ et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24(21), 4475–4481 (2006).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Sahly HE, King J et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29(44), 7733–7739 (2011).
   PubMed Web of Science ®Google Scholar
• Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis. 171(6), 1595–1599 (1995).
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Ensor K et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 29(12), 2272–2278 (2011).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Cox MM, Reisinger K et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine 27(47), 6589–6594 (2009).
   PubMed Web of Science ®Google Scholar
• Weis W, Brown JH, Cusack S et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333(6172), 426–431 (1988).
   PubMed Web of Science ®Google Scholar
• McGeoch D, Fellner P, Newton C Influenza virus genome consists of eight distinct RNA species. Proc. Natl Acad. Sci. USA. 73(9), 3045–3049 (1976).
   PubMed Web of Science ®Google Scholar
• Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9(8), 590–603 (2011).
   PubMed Web of Science ®Google Scholar
• Chen BJ, Leser GP, Jackson D et al. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 82(20), 10059–10070 (2008).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK. Influenza virus hemagglutinin cleavage into HA1, HA2: no laughing matter. Proc. Natl Acad. Sci. USA. 95(17), 9713–9715 (1998).
   PubMed Web of Science ®Google Scholar
• Webster RG, Laver WG, Kilbourne ED. Reactions of antibodies with surface antigens of influenza virus. J. Gen. Virol. 3(3), 315–326 (1968).
   PubMed Web of Science ®Google Scholar
• Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 6(4), 341–356 (1989).
   PubMed Web of Science ®Google Scholar
• Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40(3), 627–633 (1985).
   PubMed Web of Science ®Google Scholar
• Hause BM, Ducatez M, Collin EA et al. Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses. PLoS Pathog. 9(2), e1003176 (2013).
   PubMed Web of Science ®Google Scholar
• Fouchier RA, Munster V, Wallensten A et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79(5), 2814–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Air GM, Laver WG, Webster RG. Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase. J. Virol. 64(12), 5797–5803 (1990).
   PubMed Web of Science ®Google Scholar
• Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc. Natl Acad. Sci. USA. 109(11), 4269–4274 (2012).
   PubMed Web of Science ®Google Scholar
• Shortridge KF, Butterfield WK, Webster RG et al. Isolation and characterization of influenza A viruses from avian species in Hong Kong. Bull. World Health Organ. 55(1), 15–20 (1977).
   PubMed Web of Science ®Google Scholar
• Webster RG, Yakhno M, Hinshaw VS et al. Intestinal influenza: replication and characterization of influenza viruses in ducks. Virology 84(2), 268–278 (1978).
   PubMed Web of Science ®Google Scholar
• Hayden F, Croisier A. Transmission of avian influenza viruses to and between humans. J. Infect. Dis. 192(8), 1311–1314 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ito T, Suzuki T et al. Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol. 74(24), 11825–11831 (2000).
   PubMed Web of Science ®Google Scholar
• Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088), 1534–1541 (2012).
   PubMed Web of Science ®Google Scholar
• Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403), 420–428 (2012).
   PubMed Web of Science ®Google Scholar
• Maines TR, Chen LM, Van HN et al. Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology 413(1), 139–147 (2011).
   PubMed Web of Science ®Google Scholar
• Van HN, Pappas C, Belser JA et al. Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc. Natl Acad. Sci. USA. 106(9), 3366–3371 (2009).
   PubMed Web of Science ®Google Scholar
• Scholtissek C. Source for influenza pandemics. Eur. J Epidemiol. 10(4), 455–458 (1994).
   PubMed Web of Science ®Google Scholar
• Scholtissek C, Rohde W, Von H, V et al. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 87(1), 13–20 (1978).
   PubMed Web of Science ®Google Scholar
• Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 302(5650), 1519–1522 (2003).
   PubMed Web of Science ®Google Scholar
• Barr IG, McCauley J, Cox N et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine 28(5), 1156–1167 (2010).
   PubMed Web of Science ®Google Scholar
• Vijaykrishna D, Poon LL, Zhu HC et al. Reassortment of pandemic H1N1/2009 influenza A virus in swine. Science 328(5985), 1529 (2010).
   PubMed Web of Science ®Google Scholar
• Scholtissek C. Molecular aspects of the epidemiology of virus disease. Experientia 43(11–12), 1197–1201 (1987).
   PubMedGoogle Scholar
• Matrosovich M, Tuzikov A, Bovin N et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J. Virol. 74(18), 8502–8512 (2000).
   PubMed Web of Science ®Google Scholar
• Shinde V, Bridges CB, Uyeki TM et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N. Engl. J. Med. 360(25), 2616–2625 (2009).
   PubMed Web of Science ®Google Scholar
• Lee VJ, Chen MI, Chan SP et al. Influenza pandemics in Singapore, a tropical, globally connected city. Emerg. Infect. Dis. 13(7), 1052–1057 (2007).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12(1), 9–14 (2006).
   PubMed Web of Science ®Google Scholar
• Cillons SD, Lehmann J. Trends and epidemics of influenza and pneumonia: 1918–1951. Public Health Rep. 66(46), 1487–1516 (1951).
   PubMed Web of Science ®Google Scholar
• Langmuir AD, Pizzi M, Trotter WY et al. Asian influenza surveillance. Public Health Rep. 73(2), 114–120 (1958).
   PubMed Web of Science ®Google Scholar
• Choppin PW, Murphy JS, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. III. Morphological characteristics: independence to morphological and functional traits. J. Exp. Med. 112, 945–952 (1960).
   PubMed Web of Science ®Google Scholar
• Monto AS, Davenport FM, Napier JA et al. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull. World Health Organ. 41(3), 537–542 (1969).
   PubMed Web of Science ®Google Scholar
• Mulder J, Masurel N. Pre-epidemic antibody against 1957 strain of Asiatic influenza in serum of older people living in the Netherlands. Lancet 1(7025), 810–814 (1958).
   PubMed Web of Science ®Google Scholar
• Eickhoff TC. Immunization against influenza: rationale and recommendations. J. Infect. Dis. 123(4), 446–454 (1971).
   PubMed Web of Science ®Google Scholar
• Cockburn WC, Delon PJ, Ferreira W. Origin and progress of the 1968–69 Hong Kong influenza epidemic. Bull. World Health Organ. 41(3), 345–348 (1969).
   PubMed Web of Science ®Google Scholar
• Dowdle WR, Marine WM, Coleman M et al. Haemagglutinin relationships of Hong Kong(H3) and Asian(H2) influenza strains delineated by antigen-specific recombinants. J. Gen. Virol. 16(2), 127–134 (1972).
   PubMed Web of Science ®Google Scholar
• Kendal AP, Goldfield M, Noble GR et al. Identification and preliminary antigenic analysis of swine influenza-like viruses isolated during an influenza outbreak at Fort Dix, New Jersey. J. Infect. Dis. 136( Suppl.), S381–S385 (1977).
   Web of Science ®Google Scholar
• Nakajima K, Desselberger U, Palese P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature 274(5669), 334–339 (1978).
   PubMed Web of Science ®Google Scholar
• Raymond FL, Caton AJ, Cox NJ et al. The antigenicity and evolution of influenza H1 haemagglutinin, from 1950. Virology 148(2), 275–287 (1986).
   PubMed Web of Science ®Google Scholar
• Foy HM, Cooney MK, Taylor J et al. Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977–1979. J. Infect. Dis. 142(2), 139–144 (1980).
   PubMed Web of Science ®Google Scholar
• Klimov AI, Garten R, Russell C et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine 30(45), 6461–6471 (2012).
   PubMed Web of Science ®Google Scholar
• Girard MP, Tam JS, Assossou OM et al. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28(31), 4895–4902 (2010).
   PubMed Web of Science ®Google Scholar
• Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12(9), 687–695 (2012).
   PubMed Web of Science ®Google Scholar
• Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J Med. 360(25), 2605–2615 (2009).
   PubMed Web of Science ®Google Scholar
• McCullers JA, d van V, Allison KJ et al. Recipients of vaccine against the 1976 ‘swine flu’ have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin. Infect. Dis. 50(11), 1487–1492 (2010).
   PubMed Web of Science ®Google Scholar
• Manicassamy B, Medina RA, Hai R et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6(1), e1000745 (2010).
   PubMed Web of Science ®Google Scholar
• Wang W, Anderson CM, De Feo CJ et al. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS. Pathog. 7(6), e1002081 (2011).
   Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J Jr. An influenza A H1N1 virus revival-pandemic H1N1/09 virus. Infection 37(5), 381–389 (2009).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De SG, Crowcroft NS et al. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med. 7(4), e1000258 (2010).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Klimov A, Katz J et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279(5349), 393–396 (1998).
   PubMed Web of Science ®Google Scholar
• Stegeman A, Bouma A, Elbers AR et al. Avian influenza A virus (H7N7) epidemic in the Netherlands in 2003: course of the epidemic and effectiveness of control measures. J. Infect. Dis. 190(12), 2088–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Fouchier RA, Schneeberger PM, Rozendaal FW et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl Acad. Sci. USA 101(5), 1356–1361 (2004).
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368(20), 1888–1897 (2013).
   PubMed Web of Science ®Google Scholar
• Peiris M, Yuen KY, Leung CW et al. Human infection with influenza H9N2. Lancet 354(9182), 916–917 (1999).
   PubMed Web of Science ®Google Scholar
• Neumann G, Chen H, Gao GF et al. H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 20(1), 51–61 (2010).
   PubMed Web of Science ®Google Scholar
• Fleming A. Review of the development of the antibiotics, principles underlying choice of a particular antibiotic for a particular patient; the combination of different antibiotics. Acta Med. Scand. 146(1), 65–66 (1953).
   PubMedGoogle Scholar
• Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198(7), 962–970 (2008).
   PubMed Web of Science ®Google Scholar
• Chien YW, Klugman KP, Morens DM. Bacterial pathogens and death during the 1918 influenza pandemic. N. Engl. J. Med. 361(26), 2582–2583 (2009).
   PubMed Web of Science ®Google Scholar
• Chien YW, Klugman KP, Morens DM. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J. Infect. Dis. 202(11), 1639–1648 (2010).
   PubMed Web of Science ®Google Scholar
• Smith W, Manch MD, Andrewes CH et al. A virus obtained from influenza patients. Lancet 222(5732), 66–68 (1933).
   Google Scholar
• Francis T Jr. A new type of virus from epidemic influenza. Science 92(2392), 405–408 (1940).
   PubMedGoogle Scholar
• Francis T, Salk JE, Pearson HE et al. Protective effect of vaccination against induced influenza A. J. Clin. Invest 24(4), 536–546 (1945).
   PubMed Web of Science ®Google Scholar
• Salk JE, Pearson HE, Brown PN et al. Protective effect of vaccination against induced influenza B. J. Clin. Invest 24(4), 547–553 (1945).
   PubMed Web of Science ®Google Scholar
• Sartwell PE, Long AP. The army experience with influenza, 1946–1947; epidemiological aspects. Am. J. Hyg. 47(2), 135–141 (1948).
   PubMed Web of Science ®Google Scholar
• Francis T, Salk JE, Quilligan JJ. Experience with vaccination against influenza in the Spring of 1947: a preliminary report. Am. J. Public Health Nations. Health 37(8), 1013–1016 (1947).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Smith C, Brett I et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc. Natl Acad. Sci. USA. 99(16), 10748–10752 (2002).
   PubMed Web of Science ®Google Scholar
• Rasmussen AF Jr, Stokes JC, Smadel JE. The army experience with influenza, 1946–1947; laboratory aspects. Am. J. Hyg. 47(2), 142–149 (1948).
   PubMed Web of Science ®Google Scholar
• Salk JE, Suriano PC. Importance of antigenic composition of influenza virus vaccine in protecting against the natural disease; observations during the Winter of 1947–1948. Am. J. Public Health Nat. Health 39(3), 345–355 (1949).
   PubMed Web of Science ®Google Scholar
• Payne AM. The influenza programme of WHO. Bull. World Health Organ. 8(5–6), 755–774 (1953).
   PubMedGoogle Scholar
• Mostow SR, Schoenbaum SC, Dowdle WR et al. Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses. Bull. World Health Organ. 41(3), 525–530 (1969).
   PubMed Web of Science ®Google Scholar
• Welty PB Jr, Epstein B, O'Brien J et al. Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. II. Immunization of children with influenza A/New Jersey/X-53 virus vaccines. J. Infect. Dis. 136( Suppl.), S609–S611 (1977).
   PubMed Web of Science ®Google Scholar
• Allison JE, Glezen WP, Taber LH et al. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. J. Infect. Dis. 136( Suppl.), S672–S676 (1977).
   PubMed Web of Science ®Google Scholar
• Boyer KM, Cherry JD, Welliver RC et al. Clinical trials with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza vaccines in Los Angeles children. J. Infect. Dis. 136( Suppl.), S661–S664 (1977).
   PubMed Web of Science ®Google Scholar
• Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J. Hyg. (Lond). 92(3), 263–276 (1984).
   PubMedGoogle Scholar
• Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP)-United States, 2012–13 influenza season. MMWR Morb. Mortal. Wkly. Rep. 61(32), 613–618 (2012).
   PubMedGoogle Scholar
• Kung HC, Huang KC, Kao TM et al. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 28(45), 7337–7343 (2010).
   PubMed Web of Science ®Google Scholar
• Poland GA. The 2009–2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine 28( Suppl. 28), D3–D13 (2010).
   Google Scholar
• Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel-United States, August 2009–January 2010. MMWR Morb. Mortal. Wkly. Rep. 59(12), 357–362 (2010).
   PubMedGoogle Scholar
• Borse RH, Shrestha SS, Fiore AE et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009–2010. Emerg. Infect. Dis. 19(3), 439–448 (2013).
   PubMed Web of Science ®Google Scholar
• Langley JM, Scheifele DW, Quach C et al. Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12. Vaccine 30(23), 3389–3394 (2012).
   PubMed Web of Science ®Google Scholar
• Update: influenza activity-United States, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 60(21), 705–712 (2011).
   PubMedGoogle Scholar
• Francis T Jr. Vaccination against influenza. Bull. World Health Organ. 8(5–6), 725–741 (1953).
   PubMedGoogle Scholar
• Davenport FM, Hennessy AV, Brandon FM et al. Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. J. Lab Clin. Med. 63, 5–13 (1964).
   PubMed Web of Science ®Google Scholar
• Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature 213(5076), 612–614 (1967).
   PubMed Web of Science ®Google Scholar
• Kiseleva IV, Voeten JT, Teley LC et al. PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B/USSR/60/69 influenza master donor virus. J. Gen. Virol. 91(Pt 4), 931–937 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Tyrrell DA, Oxford JS et al. Infectivity and reactogenicity of reassortant cold-adapted influenza A/Korea/1/82 vaccines obtained from the USA and USSR. Bull. World Health Organ. 65(3), 295–301 (1987).
   PubMed Web of Science ®Google Scholar
• Davenport FM, Minuse E, Hennessy AV et al. Interpretations of influenza antibody patterns of man. Bull. World Health Organ. 41(3), 453–460 (1969).
   PubMed Web of Science ®Google Scholar
• Francis T. Dissociation of hemagglutinin and antibody-measuring capacities of influenza virus. J. Exp. Med. 85(1), 1–7 (1947).
   PubMed Web of Science ®Google Scholar
• Francis T, Magill TP. Immunological studies with the virus of influenza. J. Exp. Med. 62(4), 505–516 (1935).
   PubMedGoogle Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181(3), 1133–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Laver WG, Webster RG. Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutination proteins. Virology 34(2), 193–202 (1968).
   PubMed Web of Science ®Google Scholar
• Das SR, Puigbo P, Hensley SE et al. Glycosylation focuses sequence variation in the influenza a virus h1 hemagglutinin globular domain. PLoS Pathog. 6(11), e1001211 (2010).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR–8), 1–62 (2010).
   PubMedGoogle Scholar
• Hoffmann E, Krauss S, Perez D et al. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20(25–26), 3165–3170 (2002).
   PubMed Web of Science ®Google Scholar
• Greenbaum BD, Li OT, Poon LL et al. Viral reassortment as an information exchange between viral segments. Proc. Natl Acad. Sci. USA. 109(9), 3341–3346 (2012).
   PubMed Web of Science ®Google Scholar
• Fulvini AA, Ramanunninair M, Le J et al. Gene constellation of influenza a virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS ONE 6(6), e20823 (2011).
   PubMed Web of Science ®Google Scholar
• Robertson JS, Nicolson C, Harvey R et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29(9), 1836–1843 (2011).
   PubMed Web of Science ®Google Scholar
• Chen Z, Aspelund A, Kemble G et al. Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines. Virology 380(2), 354–362 (2008).
   PubMed Web of Science ®Google Scholar
• Chan W, Zhou H, Kemble G et al. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380(2), 304–311 (2008).
   PubMed Web of Science ®Google Scholar
• Chen Z, Aspelund A, Kemble G et al. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 345(2), 416–423 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Mahmood K, Yang CF et al. Rescue of influenza B virus from eight plasmids. Proc. Natl Acad. Sci. USA. 99(17), 11411–11416 (2002).
   PubMed Web of Science ®Google Scholar
• Enserink M. Influenza. Crisis underscores fragility of vaccine production system. Science 306(5695), 385 (2004).
   PubMed Web of Science ®Google Scholar
• Peiris JS, de J, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20(2), 243–267 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J, Mani S, Schwartz R et al. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28(5), 1285–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Willyard C. Cell-based vaccines yield only modest advances for seasonal flu. Nat. Med. 19(1), 4 (2013).
   PubMed Web of Science ®Google Scholar
• Onions D, Egan W, Jarrett R et al. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38(5), 544–551 (2010).
   PubMed Web of Science ®Google Scholar
• James JM, Zeiger RS, Lester MR et al. Safe administration of influenza vaccine to patients with egg allergy. J. Pediatr. 133(5), 624–628 (1998).
   PubMed Web of Science ®Google Scholar
• Polley JR, Guerin MM. The use of beta-propiolactone for the preparation of virus vaccines. II. Antigenicity. Can. J. Microbiol. 3(6), 871–877 (1957).
   PubMed Web of Science ®Google Scholar
• Polley JR, Guerin MM. The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions. Can. J. Microbiol. 3(6), 863–870 (1957).
   PubMed Web of Science ®Google Scholar
• Cleeland R, Grunberg E, Prince HN. Inactivation of the hemagglutinins of type A influenza viruses by physical and chemical means: an aid to classification. Infect. Immun. 5(3), 324–331 (1972).
   PubMed Web of Science ®Google Scholar
• Oxford JS, Potter CW, McLaren C et al. Inactivation of influenza and other viruses by a mixture of virucidal compounds. Appl. Microbiol. 21(4), 606–610 (1971).
   PubMedGoogle Scholar
• Webster RG, Glezen WP, Hannoun C et al. Potentiation of the immune response to influenza virus subunit vaccines. J. Immunol. 119(6), 2073–2077 (1977).
   PubMed Web of Science ®Google Scholar
• Russ G, Ruttkay-Nedecky G, Mucha V. Electrophoretic separation and characterization of subunits released from influenza virus by detergents. Acta Virol. 20(1), 1–8 (1976).
   PubMed Web of Science ®Google Scholar
• Powell TJ, Peng Y, Berthoud TK et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS ONE 8(5), e62778 (2013).
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55(1), 9–25 (2012).
   Web of Science ®Google Scholar
• Lambe T. Novel viral vectored vaccines for the prevention of influenza. Mol. Med. 18, 1153–1160 (2012).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Fynan EF, Webster RG, Fuller DH et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA. 90(24), 11478–11482 (1993).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11(9), 957–960 (1993).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JW et al. DNA vaccines. Annu. Rev. Immunol. 15, 617–648 (1997).
   PubMed Web of Science ®Google Scholar
• Faurez F, Dory D, Le M, V et al. Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine 28(23), 3888–3895 (2010).
   PubMed Web of Science ®Google Scholar
• Cui Z. DNA vaccine. Adv. Genet. 54, 257–289 (2005).
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Gordon IJ et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin. Vaccine Immunol. 19(11), 1792–1797 (2012).
   PubMedGoogle Scholar
• Jones S, Evans K, Elwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27(18), 2506–2512 (2009).
   PubMed Web of Science ®Google Scholar
• Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine 30(10), 1759–1766 (2012).
   PubMed Web of Science ®Google Scholar
• Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J. Invertebr. Pathol. 107( Suppl.), S31–S41 (2011).
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma S, Verma N et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 85(3), 1246–1256 (2011).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39), 5761–5769 (2012).
   PubMed Web of Science ®Google Scholar
• Wang K, Holtz KM, Anderson K et al. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 24(12), 2176–2185 (2006).
   PubMed Web of Science ®Google Scholar
• Cox MM, Anderson DK. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza. Other Respi. Viruses. 1(1), 35–40 (2007).
   PubMed Web of Science ®Google Scholar
• Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339(2), 273–280 (2005).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Beirnaert E, Neirynck S et al. Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Arch. Virol. 141(9), 1715–1726 (1996).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Maertens G, Jou WM et al. Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine 11(12), 1185–1187 (1993).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13–14), 1732–1737 (2001).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297(14), 1577–1582 (2007).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or = 65 years old. Vaccine 28(2), 379–385 (2009).
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 Years. J. Infect. Dis. 207(12), 1878–1887 (2013).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 8(1), 81–88 (2012).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Laver WG, Schulman JL et al. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2(4), 281–288 (1968).
   PubMed Web of Science ®Google Scholar
• Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 2(8), 778–786 (1968).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Pokorny BA, Johansson B et al. Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. 189(3), 459–461 (2004).
   PubMed Web of Science ®Google Scholar
• Johansson, BE, Price PM, Kilbourne ED. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 13(9), 841–845 (1995).
   PubMed Web of Science ®Google Scholar
• Fiers W, De FM, Bakkouri KE et al. M2e-based universal influenza A vaccine. Vaccine 27(45), 6280–6283 (2009).
   PubMed Web of Science ®Google Scholar
• Schotsaert M, De FM, Fiers W et al. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert. Rev. Vaccines. 8(4), 499–508 (2009).
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Keitel WA et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 31(1), 190–195 (2012).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ. 41(3), 643–645 (1969).
   PubMed Web of Science ®Google Scholar
• Hocart M, Grajower B, Donabedian A et al. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 13(18), 1793–1798 (1995).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13(18), 1799–1803 (1995).
   PubMed Web of Science ®Google Scholar
• Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17(15–16), 2073–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63(3), 1239–1246 (1989).
   PubMed Web of Science ®Google Scholar
• Erickson AH, Kilbourne ED. Comparative amino acid analysis of influenza A viral proteins. Virology 100(1), 34–42 (1980).
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Franco LM et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207(6), 974–981 (2013).
   PubMed Web of Science ®Google Scholar
• Sandbulte MR, Jimenez GS, Boon AC et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2007).
   PubMed Web of Science ®Google Scholar
• Kim MC, Lee JS, Kwon YM et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res. 99(3), 328–335 (2013).
   PubMed Web of Science ®Google Scholar
• Black RA, Rota PA, Gorodkova N et al. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74(Pt 1), 143–146 (1993).
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62(8), 2762–2772 (1988).
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol. 56(2), 502–511 (1985).
   PubMed Web of Science ®Google Scholar
• Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 342(2), 215–227 (2005).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172(9), 5598–5605 (2004).
   PubMed Web of Science ®Google Scholar
• El BK, Descamps F, De FM et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186(2), 1022–1031 (2011).
   PubMed Web of Science ®Google Scholar
• Huber VC, Lynch JM, Bucher DJ et al. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166(12), 7381–7388 (2001).
   PubMed Web of Science ®Google Scholar
• Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393–5399 (2008).
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van HN et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283–4290 (2007).
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE 4(6), e6032 (2009).
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826–7834 (2011).
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trepanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
   PubMed Web of Science ®Google Scholar
• Cwach KT, Sandbulte HR, Klonoski JM et al. Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays. Influenza. Other Respi. Viruses 6(2), 127–135 (2012).
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.). 70(4), 767–777 (1972).
   PubMedGoogle Scholar
• Hobson D, Baker FA, Chivers CP et al. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines. J. Hyg. (Lond.). 68(3), 369–378 (1970).
   PubMedGoogle Scholar
• McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum. Vaccin. Immunother. 8(1), 34–44 (2012).
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37(4), 937–943 (1999).
   PubMed Web of Science ®Google Scholar
• Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10. Vaccine 26(34), 4299–4303 (2007).
   Web of Science ®Google Scholar
• Makizumi K, Kimachi K, Fukada K et al. Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 26(52), 6852–6858 (2008).
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Friesen RH, Bhabha G et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333(6044), 843–850 (2011).
   PubMed Web of Science ®Google Scholar
• Bommakanti G, Lu X, Citron MP et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 86(24), 13434–13444 (2012).
   PubMed Web of Science ®Google Scholar
• Bommakanti G, Citron MP, Hepler RW et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl Acad. Sci. USA. 107(31), 13701–13706 (2010).
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang T et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1(1), e00018 (2010).
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R et al. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 86(19), 10302–10307 (2012).
   PubMed Web of Science ®Google Scholar
• Schneemann A, Speir JA, Tan GS et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J. Virol. 86(21), 11686–11697 (2012).
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA. 107(44), 18979–18984 (2010).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA. 87(2), 786–790 (1990).
   PubMed Web of Science ®Google Scholar